1 Min Read
May 30 (Reuters) - Advaxis Inc
* Advaxis and Bristol-Myers Squibb announce clinical collaboration to evaluate ADXS-DUAL and opdivo (nivolumab) in metastatic cervical cancer
* Bristol-Myers Squibb Co says Advaxis will sponsor study and pay third-party costs
* Bristol-Myers Squibb Co - Under terms of agreement, each party will bear their own internal costs and provide its immunotherapy agents.
* Bristol-Myers squibb -Study expected to start by end of year Source text for Eikon: Further company coverage: